On December 17, 2020, Betta Pharmaceuticals Co., Ltd. (SZSE:300558) closed the transaction. The company amended the terms of the transaction. The company issued 10,138,621 shares at a price of CNY 98.83 per share for gross proceeds of CNY 1,001,999,913.43.

The transaction included participation from J.P. Morgan Securities Ltd., Investment Arm for CNY 46,999,990.12, UBS AG for CNY 39,999,960.05, Penghua Fund Management Co. Ltd. for CNY 114,999,971.62, Yinhua Fund Management Co. Ltd. for CNY 159,999,939.03, Hongde Fund Management Co., Ltd. for CNY 143,579,927.51, ABC-CA Fund Management Co., Ltd. for CNY 62,240,465.59, Maanshan Zhongan Cornerstone Yangtze River Delta Development New Momentum Fund Partnership (Limited partnership) for CNY 99,999,949.54, China Galaxy Securities Co., Ltd., Investment Arm for CNY 99,999,949.54, Caitong Fund Management Co., Ltd. for CNY 62,999,974.14, Luxin Venture Capital Group Co., Ltd. (SHSE:600783) for CNY 49,999,974.77, Hongwei Cornerstone Huade No.

1 Private Securities Investment Fund, a fund managed by Wuhu Hongwei Cornerstone Investment Fund Management Partnership (Limited Partnership) for CNY 31,179,975.5, Hunan Xiangtou Army Financial Industry Investment Fund Enterprise (Limited Partnership) for CNY 29,999,945.33, Fu An Trading (Jiangmen) Co., Ltd for CNY 29,999,945.33, and individual investor for CNY 29,999,945.33. The company paid and issuance expenses for CNY 6,594,538.73, brining the net proceeds to CNY 995,405,374.70. All the securities issued shall not be transferred within 6 months from the end of the issuance.